Brigatinib in crizotinib-refractory ALK plus non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial

D. Kim; R. Huber; M. Ahn; C. Langer; M. Tiseo; H. West; H. Groen; K. Reckamp; M. Hochmair; N. Leighl; K. H. Hansen; S. Gettinger; L. Paz-Ares Rodriguez; E. Kim; E. Smit; S. Kim; W. Reichmann; D. Kerstein; D. R. Camidge

doi:10.1016/S0169-5002(19)30120-5

Brigatinib in crizotinib-refractory ALK plus non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial

D. Kim, R. Huber, M. Ahn, C. Langer, M. Tiseo, H. West, H. Groen, K. Reckamp, M. Hochmair, N. Leighl, K. H. Hansen, S. Gettinger, L. Paz-Ares Rodriguez, E. Kim, E. Smit, S. Kim, W. Reichmann, D. Kerstein, D. R. Camidge

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	S30-S31
Number of pages	3
Journal	Lung Cancer
Volume	127
DOIs	https://doi.org/10.1016/S0169-5002(19)30120-5
Publication status	Published - Jan-2019

Access to Document

10.1016/S0169-5002(19)30120-5

Handle.net

Persistent link

Cite this

Kim, D., Huber, R., Ahn, M., Langer, C., Tiseo, M., West, H., Groen, H., Reckamp, K., Hochmair, M., Leighl, N., Hansen, K. H., Gettinger, S., Paz-Ares Rodriguez, L., Kim, E., Smit, E., Kim, S., Reichmann, W., Kerstein, D., & Camidge, D. R. (2019). Brigatinib in crizotinib-refractory ALK plus non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial. Lung Cancer, 127, S30-S31. https://doi.org/10.1016/S0169-5002(19)30120-5

@article{9baf08c26be7441197bd210c2a8814a6,

title = "Brigatinib in crizotinib-refractory ALK plus non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial",

author = "D. Kim and R. Huber and M. Ahn and C. Langer and M. Tiseo and H. West and H. Groen and K. Reckamp and M. Hochmair and N. Leighl and Hansen, {K. H.} and S. Gettinger and {Paz-Ares Rodriguez}, L. and E. Kim and E. Smit and S. Kim and W. Reichmann and D. Kerstein and Camidge, {D. R.}",

year = "2019",

month = jan,

doi = "10.1016/S0169-5002(19)30120-5",

language = "English",

volume = "127",

pages = "S30--S31",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "ELSEVIER IRELAND LTD",

}

Kim, D, Huber, R, Ahn, M, Langer, C, Tiseo, M, West, H, Groen, H, Reckamp, K, Hochmair, M, Leighl, N, Hansen, KH, Gettinger, S, Paz-Ares Rodriguez, L, Kim, E, Smit, E, Kim, S, Reichmann, W, Kerstein, D & Camidge, DR 2019, 'Brigatinib in crizotinib-refractory ALK plus non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial', Lung Cancer, vol. 127, pp. S30-S31. https://doi.org/10.1016/S0169-5002(19)30120-5

TY - JOUR

T1 - Brigatinib in crizotinib-refractory ALK plus non-small cell lung cancer (NSCLC)

T2 - efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial

AU - Kim, D.

AU - Huber, R.

AU - Ahn, M.

AU - Langer, C.

AU - Tiseo, M.

AU - West, H.

AU - Groen, H.

AU - Reckamp, K.

AU - Hochmair, M.

AU - Leighl, N.

AU - Hansen, K. H.

AU - Gettinger, S.

AU - Paz-Ares Rodriguez, L.

AU - Kim, E.

AU - Smit, E.

AU - Kim, S.

AU - Reichmann, W.

AU - Kerstein, D.

AU - Camidge, D. R.

PY - 2019/1

Y1 - 2019/1

U2 - 10.1016/S0169-5002(19)30120-5

DO - 10.1016/S0169-5002(19)30120-5

M3 - Meeting Abstract

SN - 0169-5002

VL - 127

SP - S30-S31

JO - Lung Cancer

JF - Lung Cancer

ER -